MP01-11 EVALUATION OF miRNA-371a-3p (miR371a) ASSAY IN PATIENTS UNDERGOING INGUINAL ORCHIDECTOMY OR ENUCLEATION FOR SUSPECTED TESTICULAR TUMOR

You have accessJournal of UrologyPenile & Testicular Cancer I (MP01)1 May 2024MP01-11 EVALUATION OF miRNA-371a-3p (miR371a) ASSAY IN PATIENTS UNDERGOING INGUINAL ORCHIDECTOMY OR ENUCLEATION FOR SUSPECTED TESTICULAR TUMOR Felix Seelemeyer, David Pfister, Roberto Pappesch, Sabine Markelbach-Bruse, and Axel Heidenreich Felix SeelemeyerFelix Seelemeyer , David PfisterDavid Pfister , Roberto PappeschRoberto Pappesch , Sabine Markelbach-BruseSabine Markelbach-Bruse , and Axel HeidenreichAxel Heidenreich View All Author Informationhttps://doi.org/10.1097/01.JU.0001008660.87408.90.11AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: In the literature, miR371a has a sensitivity of >90% for seminomas and non-seminomas (NSGCT) with the exception of teratomas. Even in small tumors of <1 cm, marker expression is present in >80% of all cases. In collaboration with pathology, we are evaluating the test for detection of miR371a in patients undergoing inguinal testicular exposure for suspected testicular tumors in clinical practice. METHODS: Surgery was performed between 03/2022–08/2023 in 47 patients. Cubital vein blood is sent to molecular pathology within 30min for extraction of miR371a. The Maxwell RSC with the Maxwell® RSC MiRNA Plasma and Serum Kits is used here to extract and purify the miRNA. The extracted miRNA is transcribed into cDNA using cDNA Solution, Reverse Transcriptase and RNase Inhibitor. Subsequently, this cDNA is amplified. Using qPCR (Real Time-quantitative Polymerase Chain Reaction), the micro RNA 371a is quantified using Roche Lightcycler 480 II. Using the Lightcycler software, the median Cp (CP=crossing points) of the triplicates is calculated and converted into a RQ value (RQ=relative abundance). RESULTS: The evaluation of the miRNA assay showed a correct positive result with regard to histology for the total cohort of patients with inguinal exploration and either orchiectomy or organ sparing surgery in 70% of the patients (18x seminoma as well as 1x yolk sac tumor, 1x embryonal carcinoma, 1x somatic metastasis). False-negative findings were present in 30% of patients (8x seminoma, 1x embryonal cell carcinoma). A false positive result presented in one patient with teratoma, as well as in three patients with benign histology. A true negative result was identified in 81.2% of patients (9x benign histology, 2x Leydig cell tumor, 1x lymphoma, 1x Sarcoma). In comparison, the classic tumor markers (ß-HCG, AFP, LDH) were correctly positive in only 23.1% of the malignant histologies and false negative in 76.9%. The classical tumor markers showed no false-negative result. CONCLUSIONS: In the absence of suitable markers, miR371a shows promising results in the preoperative diagnosis for testicular tumors with uncertain histology and it is superior to classical tumor markers. However, a negative test does not rule out malignancy so that patients still need to undergo inguinal surgery. Source of Funding: This work was supported by Department of Urology, Uniklinik Köln © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e6 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Felix Seelemeyer More articles by this author David Pfister More articles by this author Roberto Pappesch More articles by this author Sabine Markelbach-Bruse More articles by this author Axel Heidenreich More articles by this author Expand All Advertisement PDF downloadLoading ...